CDK1 structures reveal conserved and unique features of the essential cell cycle CDK

Nature Communications

Volumn 6, Issue , 2015, Pages

  Brown, Nicholas R ^a,c   Korolchuk, Svitlana ^b   Martin, Mathew P ^b   Stanley, Will A ^b   Moukhametzianov, Rouslan ^b   Noble, Martin E M ^a,b   Endicott, Jane A ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; ADENOSINE TRIPHOSPHATE; CARRIER PROTEIN; CDK1 PROTEIN, HUMAN; CDK2 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CKS1B PROTEIN, HUMAN; CKS2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; HYBRID PROTEIN; PEPTIDE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

CRYSTAL STRUCTURE; CYTOLOGY; EUKARYOTE;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DEPHOSPHORYLATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; SURFACE PROPERTY; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BOVINE; CHEMICAL STRUCTURE; CHEMISTRY; CONSERVED SEQUENCE; ENZYME SPECIFICITY; GENE EXPRESSION; GENETICS; HUMAN; KINETICS; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

EUKARYOTA;

ADENOSINE TRIPHOSPHATE; ANIMALS; BINDING, COMPETITIVE; CARRIER PROTEINS; CATTLE; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; CYCLIN A; CYCLIN B; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; GENE EXPRESSION; HUMANS; KINETICS; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84927750305     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7769     Document Type: Article

References (70)

1. Lohka, M. J., Hayes, M. K. & Maller, J. L. Purification of maturation-promoting factor, an intracellular regulator of early mitotic events. Proc. Natl Acad. Sci. USA 85, 3009-3013 (1988).
2. Draetta, G., Brizuela, L., Potashkin, J. & Beach, D. Identification of p34 and p13, human homologs of the cell cycle regulators of fission yeast encoded by cdc2 + and suc1 +. Cell 50, 319-325 (1987).
3. Lee, M. G. & Nurse, P. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 327, 31-35 (1987).
4. Morgan, D. O. The cell cycle: principles of control (Oxford University Press, 2007).
5. Pines, J. & Hunter, T. Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature 346, 760-763 (1990).
6. Giordano, A. et al. A 60 kd cdc2-associated polypeptide complexes with the E1A proteins in adenovirus-infected cells. Cell 58, 981-990 (1989).
7. Labib, K. How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes Dev. 24, 1208-1219 (2010).
8. den Elzen, N. & Pines, J. Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase. J. Cell Biol. 153, 121-136 (2001).
9. Geley, S. et al. Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J. Cell Biol. 153, 137-148 (2001).
10. Pines, J. & Hunter, T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 58, 833-846 (1989).
11. Deibler, R. W. & Kirschner, M. W. Quantitative reconstitution of mitotic CDK1 activation in somatic cell extracts. Mol. Cell 37, 753-767 (2010).
12. Pines, J. & Hunter, T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J. Cell Biol. 115, 1-17 (1991).
13. Gavet, O. & Pines, J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev. Cell 18, 533-543 (2010).
14. Fung, T. K. & Poon, R. Y. A roller coaster ride with the mitotic cyclins. Semin. Cell Dev. Biol. 16, 335-342 (2005).
15. Lindqvist, A., Rodriguez-Bravo, V. & Medema, R. H. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J. Cell Biol. 185, 193-202 (2009).
16. Alvarez-Fernandez, M. & Malumbres, M. Preparing a cell for nuclear envelope breakdown: Spatio-temporal control of phosphorylation during mitotic entry. Bioessays 36, 757-765 (2014).
17. Holt, L. J. et al. Global analysis of Cdk1 substrate phosphorylation sites provides insights into evolution. Science 325, 1682-1686 (2009).
18. Mochida, S. & Hunt, T. Protein phosphatases and their regulation in the control of mitosis. EMBO Rep. 13, 197-203 (2012).
19. Clute, P. & Pines, J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat. Cell Biol. 1, 82-87 (1999).
20. Peters, J. M. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat. Rev. Mol. Cell Biol. 7, 644-656 (2006).
21. Barford, D. Structural insights into anaphase-promoting complex function and mechanism. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 366, 3605-3624 (2011).
22. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-166 (2009).
23. Satyanarayana, A. et al. Genetic substitution of Cdk1 by Cdk2 leads to embryonic lethality and loss of meiotic function of Cdk2. Development 135, 3389-3400 (2008).
24. Santamaria, D. et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448, 811-815 (2007).
25. Diril, M. K. et al. Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc. Natl Acad. Sci. USA 109, 3826-3831 (2012).
26. Adhikari, D. et al. Cdk1, but not Cdk2, is the sole Cdk that is essential and sufficient to drive resumption of meiosis in mouse oocytes. Hum. Mol. Genet. 21, 2476-2484 (2012).
27. Hayles, J., Beach, D., Durkacz, B. & Nurse, P. The fission yeast cell cycle control gene cdc2: isolation of a sequence suc1 that suppresses cdc2 mutant function. Mol. Gen. Genet. 202, 291-293 (1986).
28. Patra, D., Wang, S. X., Kumagai, A. & Dunphy, W. G. The xenopus Suc1/Cks protein promotes the phosphorylation of G(2)/M regulators. J. Biol. Chem. 274, 36839-36842 (1999).
29. Koivomagi, M. et al. Multisite phosphorylation networks as signal processors for Cdk1. Nat. Struct. Mol. Biol. 20, 1415-1424 (2013).
30. Koivomagi, M. et al. Cascades of multisite phosphorylation control Sic1 destruction at the onset of S phase. Nature 480, 128-131 (2011).
31. Bourne, Y. et al. Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1. Cell 84, 863-874 (1996).
32. McGrath, D. A. et al. Cks confers specificity to phosphorylation-dependent CDK signaling pathways. Nat. Struct. Mol. Biol. 20, 1407-1414 (2013).
33. Cheng, C. K. et al. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proc. Natl Acad. Sci. USA 109, 12722-12727 (2012).
34. Johnson, N. & Shapiro, G. I. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin. Ther. Targets 14, 1199-1212 (2010).
35. Johnson, N. et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat. Med. 17, 875-882 (2011).
36. Cepeda, D. et al. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol. Med. 5, 999-1018 (2013).
37. Vassilev, L. T. et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl Acad. Sci. USA 103, 10660-10665 (2006).
38. Bruyere, C. & Meijer, L. Targeting cyclin-dependent kinases in anti-neoplastic therapy. Curr. Opin. Cell Biol. 25, 772-779 (2013).
39. Malumbres, M., Pevarello, P., Barbacid, M. & Bischoff, J. R. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol. Sci. 29, 16-21 (2008).
40. Hole, A. J. et al. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity. J. Med. Chem. 56, 660-670 (2013).
41. Cho, Y. S. et al. Fragment-based discovery of 7-azabenzimidazoles as potent, highly selective, and orally active CDK4/6 inhibitors. ACS Med. Chem. Lett. 3, 445-449 (2012).
42. De Bondt, H. L. et al. Crystal structure of cyclin-dependent kinase 2. Nature 363, 595-602 (1993).
43. Jeffrey, P. D. et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376, 313-320 (1995).
44. Takaki, T. et al. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc. Natl Acad. Sci. USA 106, 4171-4176 (2009).
45. Petri, E. T., Errico, A., Escobedo, L., Hunt, T. & Basavappa, R. The crystal structure of human cyclin B. Cell Cycle 6, 1342-1349 (2007).
46. Russo, A. A., Jeffrey, P. D., Patten, A. K., Massague, J. & Pavletich, N. P. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382, 325-331 (1996).
47. Day, P. J. et al. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc. Natl Acad. Sci. USA 106, 4166-4170 (2009).
48. Baumli, S. et al. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J. 27, 1907-1918 (2008).
49. Brown, N. R. et al. Cyclin B and cyclin A confer different substrate recognition properties on CDK2. Cell Cycle 6, 1350-1359 (2007).
50. Brown, N. R., Noble, M. E., Endicott, J. A. & Johnson, L. N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1, 438-443 (1999).
51. Leng, X., Noble, M., Adams, P. D., Qin, J. & Harper, J. W. Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Mol. Cell Biol. 22, 2242-2254 (2002).
52. Larochelle, S. et al. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol. Cell 25, 839-850 (2007).
53. Desai, D., Wessling, H. C., Fisher, R. P. & Morgan, D. O. Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol. Cell Biol. 15, 345-350 (1995).
54. Larochelle, S., Pandur, J., Fisher, R. P., Salz, H. K. & Suter, B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev. 12, 370-381 (1998).
55. Merrick, K. A. et al. Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Mol. Cell 32, 662-672 (2008).
56. Noble, M. E., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 303, 1800-1805 (2004).
57. Zhao, Z. et al. Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 9, 1230-1241 (2014).
58. Wyatt, P. G. et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J. Med. Chem. 51, 4986-4999 (2008).
59. Fisher, R. P. & Morgan, D. O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 78, 713-724 (1994).
60. Schachter, M. M. et al. A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression. Mol. Cell 50, 250-260 (2013).
61. Tahirov, T. H. et al. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 465, 747-751 (2010).
62. Brown, N. R. et al. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 274, 8746-8756 (1999).
63. Brown, N. R. et al. The crystal structure of cyclin A. Structure 3, 1235-1247 (1995).
64. Welburn, J. & Endicott, J. Methods for preparation of proteins and protein complexes that regulate the eukaryotic cell cycle for structural studies. Methods Mol. Biol. 296, 219-235 (2005).
65. Evans, P. An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr. Sect. D. D67, 282-292 (2011).
66. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D. Biol. Crystallogr. 50, 760-763 (1994).
67. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
68. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D. Biol. Crystallogr. 53, 240-255 (1997).
69. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486-501 (2010).
70. McNicholas, S., Potterton, E., Wilson, K. S. & Noble, M. E. Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr. D. Biol. Crystallogr. 67, 386-394 (2011).